Medical Editor: John P. Cunha, DO, FACOEP
HepatAmine (8% Amino Acid Injection) is amino acids used to treat hepatic encephalopathy in patients with cirrhosis or hepatitis. HepatAmine provides nutritional support for patients with these diseases of the liver who require parenteral nutrition and are intolerant of general purpose amino acid injections, which are contraindicated in patients with hepatic coma. Common side effects of HepatAmine include:
- water weight gain
- low blood sodium
- fever, and
- injection site reactions (infection, swelling, or blood clots).
The total daily dose of HepatAmine depends on daily protein requirements and on the patient's metabolic and clinical response. HepatAmine may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, HepatAmine should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our HepatAmine (8% Amino Acid Injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Reactions reported in clinical studies as a result of infusion of the parenteral fluid were water weight gain, edema, increase in BUN, and dilutional hyponatremia. Asterixis was reported to have worsened in one patient during infusion of hepatamine® (amino acid) (8% Amino Acid Injection). Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Read the entire FDA prescribing information for HepatAmine (Amino Acid)
© HepatAmine Patient Information is supplied by Cerner Multum, Inc. and HepatAmine Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.